Edwards Lifesciences’ redesigned non-invasive heart valve replacement system - Sapien XT - showed good performance and was associated with fewer complications compared to the original Sapien, clinical trial researchers explained at the American College of Cardiology’s (ACC) 62nd Annual Scientific Session in San Francisco, on Saturday.
